BREAST CANCER IN MEN IN THE REPUBLIC OF BASHKORTOSTAN

Breast cancer in men is 100 times less common than in women. The principles of treatment of breast cancer in men are still based on knowledge obtained during the treatment of women with a similar pathology. The article reviews 67 cases of all breast cancer stages in men. The majority (50.7%) of all patients who initiated therapy had stage III-IV tumors. In most cases, the patients had an infiltrating ductal carcinoma (52.2%). The combination and complex treatment methods accounted for 53.6% of all cases. The radical mastectomy (89.6%) was the most frequent method of operative intervention. 29 patients (43.3%) received preoperative chemotherapy. 36 patients received adjuvant treatment. The adjuvant treatment comprised chemotherapy (29 patients), and subsequently was supplemented with antihormonal therapy in patients with receptor-positive tumors. The anthracycline-containing chemotherapy was the most prevalent among treatment regimens (72.4%). In 7 patients with a locally diffused process, the treatment was supplemented with radiotherapy. 72.2% of patients had a clinically significant estrogen receptor (RE) expression in the tumor and 61% of patients had a progesterone receptor (RP) expression. 85.0% of patients with stages I-IIA breast cancers showed the relatively high 5-year survival rates, and 67.5% of patients with stage IIB cancers showed 5-year survival. The survival rates for stages III and IV cancer were 18.1% and 16.6%, respectively.

Download Full-text

Postoperative Radiotherapy in N– Breast Cancer. A Retrospective Case-Control Study

Tumori Journal ◽

10.1177/030089168106700509 ◽

1981 ◽

Vol 67 (5) ◽

pp. 443-445 ◽

Cited By ~ 1

Author(s):

Mario Cappellini ◽

Stefano Ciatto ◽

Raffaello Mungai

Keyword(s):

Breast Cancer ◽

Case Control Study ◽

Postoperative Radiotherapy ◽

Survival Rates ◽

Radical Mastectomy ◽

Case Control ◽

Breast Cancers ◽

Breast Cancer Patients ◽

Retrospective Case ◽

Control Study

The role of postoperative radiotherapy in N- breast cancer with centrally or medially located tumors is still controversial. The authors report the results of a retrospective non-randomized case-control study of T1–2 N- breast cancer patients with centrally or medially located tumors, treated or not with postoperative radiotherapy after radical mastectomy. Sixty-four patients were treated with postoperative radiotherapy (Co-60) to the internal mammary chain and supraclavicular nodes. Sixty-four control cases, matched by T size and site, N status, age and menstrual status and simply followed-up after radical mastectomy were selected. No significant differences in actuarial recurrence and NED survival rates were observed at 5 years in the 2 compared groups, thus indicating that postoperative radiotherapy for patients with N- centrally or medially located breast cancers is not worthwhile treatment policy.

Download Full-text

Survival Outcomes in Male Breast Cancer – A Single Institution Experience

Asian Pacific Journal of Cancer Care ◽

10.31557/apjcc.2018.3.4.71 ◽

2018 ◽

Vol 3 (4) ◽

pp. 71

Author(s):

Nisha Hariharan

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

Treatment Guidelines ◽

Ductal Carcinoma ◽

Radical Mastectomy ◽

Male Breast ◽

Survival Outcomes ◽

Breast Cancers ◽

Breast Cancer Patients

Introduction: Male breast cancer is an uncommon entity. Due to the scarce numbers, treatment protocolshave largely been extrapolated from available evidence for female breast cancers.Methods: We analysed the clinicopathological features and survival outcomes for male breast cancer patients treated at our institute between January 2010 and June 2016.Results: Of the 5534 women treated at our institute, we screened 40 male breast cancers of whom 33 had available follow up data and were included in the present analysis. Male breast cancer constituted 0.7% of all breast cancers. The median age was 60 years and the median tumor size was 3cm with 66% of patients having nodal disease at presentation. Invasive ductal carcinoma was the most common histology and 97% were hormone receptor positive. Most of the patients (87.8%) underwent an upfront modified radical mastectomy. With a median follow up of 36 months, 10 patients experienced recurrences all of which were distant metastasis (3 to the bone, 1 to the brain, and 6 had visceral metastasis). Of these, 7 patients succumbed to the disease. The 3-year overall survival was 78.7 %.Conclusion: Male breast cancer is a rare clinical entity and current treatment guidelines follow those for women. Due to the lack of awareness, men often present to clinics at an advanced stage. Social support targeted at improving awareness and access to treatment could improve outcomes in this cohort.

Download Full-text

Changes in Male Breast Cancer over a 30-Year Period

The American Surgeon ◽

10.1177/000313480807400807 ◽

2008 ◽

Vol 74 (8) ◽

pp. 707-712 ◽

Cited By ~ 4

Author(s):

Nicholas Paul Schaub ◽

Nell Maloney ◽

Heather Schneider ◽

Eric Feliberti ◽

Roger Perry

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

Ductal Carcinoma ◽

Radical Mastectomy ◽

Retrospective Chart Review ◽

Male Breast ◽

Breast Cancers ◽

Breast Cancer Patients ◽

Lymph Node Mapping ◽

Presenting Symptoms

Male breast cancer is a rare clinical entity accounting for approximately 1 per cent of all breast cancers. The present study investigated changes in patient characteristics, disease patterns, treatment, and outcomes over a 30-year period. A retrospective chart review was performed on male breast cancer patients treated between 1975 and 2005 at Eastern Virginia Medical School, Norfolk, VA. Demographic, pathologic, treatment, and survival information was collected. To facilitate comparison of trends, the patients were divided into two groups: Cohort A (1972–1991, previously reported) and Cohort B (1992–2005). Both cohorts included 28 male patients. Comparing the cohorts, no statistical differences were noted in median age, ethnicity, presenting symptoms, or progesterone receptor status. In Cohort A, 70 per cent of patients were estrogen receptor positive, compared with 100 per cent of Cohort B ( P = 0.02). Her2/neu was positive in three of five patients in Cohort B. There was a trend toward more conservative surgery, with no radical mastectomy or orchiectomy performed in Cohort B. Only two patients had sentinel lymph node mapping, both from Cohort B. Infiltrating ductal carcinoma was more prevalent in Cohort B ( P = 0.04). For Cohort A and B, 5-year survival was 43 per cent and 51 per cent, respectively, which was not statistically significant. For male breast cancer, radical mastectomy is no longer a common treatment modality. Male breast cancer of today is more hormonally responsive which may have important implications for therapy. Survival has not significantly improved over the previous 30 years. Compilation of multi-institutional data of male breast cancer is needed to advance the treatment of this uncommon disease.

Download Full-text

Treatment Options for Metaplastic Breast Cancer

ISRN Oncology ◽

10.5402/2012/706162 ◽

2012 ◽

Vol 2012 ◽

pp. 1-4 ◽

Cited By ~ 13

Author(s):

Dhruvil R. Shah ◽

Warren H. Tseng ◽

Steve R. Martinez

Keyword(s):

Breast Cancer ◽

Ductal Carcinoma ◽

Treatment Options ◽

Multidisciplinary Treatment ◽

Chemotherapeutic Agents ◽

Breast Cancers ◽

Metaplastic Breast Cancer ◽

Similar Treatment ◽

Prognostic Features ◽

Treatment Regimens

Metaplastic breast cancer (MBC) is a malignancy characterized by the histologic presence of two or more cellular types, commonly a mixture of epithelial and mesenchymal components. MBC is rare relative to invasive ductal carcinoma (IDC), representing less than 1% of all breast cancers. Other than a lower rate of lymph node metastases, MBC tumors display poorer prognostic features relative to IDC. Due to its low incidence and pathological variability, the ideal treatment paradigm for MBC is unknown. Because of its rarity, MBC has been treated as a variant of IDC. Despite similar treatment regimens, however, patients with MBC have worse outcomes. Recent research is focused on biological differences between MBC and IDC and potential novel targets for chemotherapeutic agents. This paper serves as a summation of current literature on approaches to the multidisciplinary treatment of patients with MBC.

Download Full-text

Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis

BMC Cancer ◽

10.1186/s12885-021-07855-z ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Dechuang Jiao ◽

Jingyang Zhang ◽

Jiujun Zhu ◽

Xuhui Guo ◽

Yue Yang ◽

...

Keyword(s):

Breast Cancer ◽

Cox Model ◽

Survival Rates ◽

Tumor Grade ◽

Population Based ◽

Rank Test ◽

Breast Cancers ◽

Significant Independent Predictor ◽

Cancer Specific Survival ◽

7Th Edition

Abstract Background Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. Methods Surveillance, Epidemiology, and End Results (SEER) database was searched to identify cases with confirmed non-metastatic IBC and T4-non-IBC who had received surgery, chemotherapy, and radiotherapy between 2010 and 2015. IBC was defined as per the American Joint Committee on Cancer (AJCC) 7th edition. Breast Cancer-Specific Survival (BCSS) was estimated by plotting the Kaplan-Meier curve and compared across groups by using the log-rank test. Cox model was constructed to determine the association between IBC and BCSS after adjusting for age, race, stage of disease, tumor grade and surgery type. Results Out of a total of 1986 patients, 37.1% had IBC and mean age was 56.6 ± 12.4. After a median follow-up time of 28 months, 3-year BCSS rate for IBC and T4-non-IBC patients was 81.4 and 81.9%, respectively (log-rank p = 0.398). The 3-year BCSS rate in HR−/HER2+ cohort was higher for IBC patients than T4-non-IBC patients (89.5% vs. 80.8%; log-rank p = 0.028), and in HR−/HER2- cohort it was significantly lower for IBC patients than T4-non-IBC patients (57.4% vs. 67.5%; log-rank p = 0.010). However, it was identical between IBC and T4-non-IBC patients in both HR+/HER2- (85.0% vs. 85.3%; log-rank p = 0.567) and HR+/HER2+ (93.6% vs. 91.0%, log-rank p = 0.510) cohorts. After adjusting for potential confounding variables, we observed that IBC is a significant independent predictor for survival of HR−/HER2+ cohort (hazards ratio [HR] = 0.442; 95% CI: 0.216–0.902; P = 0.025) and HR−/HER2- cohort (HR = 1.738; 95% CI: 1.192–2.534; P = 0.004). Conclusions Patients with IBC and T4-non-IBC had a similar BCSS in the era of modern systemic treatment. In IBC patients, the HR−/HER2+ subtype is associated with a better outcome, and HR−/HER2- subtype is associated with poorer outcomes as compared to the T4-non-IBC patients.

Download Full-text

Descriptive analysis of 192 cases of breast cancer occurring before age 40 in Yaounde, Cameroon

International Journal of Reproduction Contraception Obstetrics and Gynecology ◽

10.18203/2320-1770.ijrcog20172898 ◽

2017 ◽

Vol 6 (7) ◽

pp. 2704 ◽

Cited By ~ 1

Author(s):

Félix Essiben ◽

Pascal Foumane ◽

Esther JNU Meka ◽

Michèle Tchakounté ◽

Julius Sama Dohbit ◽

...

Keyword(s):

Breast Cancer ◽

Ductal Carcinoma ◽

Early Stage ◽

Descriptive Analysis ◽

Survival Rates ◽

The United States ◽

Therapeutic Modalities ◽

History Of ◽

Case Files ◽

Common Histological Type

Background: Breast cancer is today a global health problem. With 1,671,149 new cases diagnosed in 2012, it is the most common female cancer in the world and accounts for 11.9% of all cancers and it affects more people than prostate cancer. In 2008, The United States statistics showed that, for all cancer that affect women before 40 years, more than 40% of them concerned the breast. The aim of this study was to describe the clinical, histopathological and therapeutic aspects of breast cancer in women under 40 years of age in Yaoundé.Methods: This was a retrospective study with data collected from 192 medical case files of women treated over a period of 12 years, from January 2004 to December 2015 at the Yaounde General Hospital and the Yaounde Gyneco-Obstetric and Pediatric Hospital. Microsoft Epi Info version 3.4.5 and SPSS version 20.0 softwares were used for data analysis.Results: From 2004 to 2015, 1489 cases of breast cancer were treated in both hospitals. Of these, 462 women were less than 40 years old, representing a proportion of 31.0%. The mean age at diagnosis was 33.5±5.0 years and 17.7% of women had a family history of breast cancer. The average time before an initial consultation was 6.7±6.6 months. Most cases were classified as T4 (46.1%). The most common histological type was ductal carcinoma (87.4%). Grades SBR II and SBR III were predominant (76.4%). Axillary dissection (64.4%) and neoadjuvant chemotherapy (43.9%) were the main therapeutic modalities. The overall survival rate at 5 years was 51.2%. Five-year survival rates with no local recurrence and no metastatic occurrence were 35.8% and 43.2% respectively.Conclusions: Breast cancer largely affects women under the age of 40 and is often discovered late, at an advanced stage. The prognosis appears poor. Only screening could facilitate diagnosis at an early stage of the disease for better outcomes.

Download Full-text

Breast Cancer Survival in the Mammography Era in Brazil: A Population-Based Analysis of 2,715 Cases

10.21203/rs.3.rs-625485/v1 ◽

2021 ◽

Author(s):

Juliana Fernandes ◽

Beatriz Machado ◽

Cassio Cardoso-Filho ◽

Juliana Nativio ◽

Cesar Cabello ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Survival ◽

Survival Rates ◽

Population Based ◽

Breast Cancer Survival ◽

Stage I ◽

Current Status ◽

Breast Cancers ◽

Risk Of Death ◽

Significant Difference

Abstract Background This study aims to assess breast cancer survival rates after one decade of mammography in a large urban area of Brazil. Methods It is a population-based retrospective cohort of women with breast cancer in Campinas, São Paulo, from 2010 to 2014. Age, vital status and stage were accessed through the cancer and mortality registry, and patients records. Statistics used Kaplan-Meier, log-rank and Cox's regression. Results Out of the 2,715 cases, 665 deaths (24.5%) were confirmed until early 2020. The mean age at diagnosis was 58.6 years. Women 50-69 years were 48.0%, and stage I the most frequent (25.0%). The overall mean survival was 8.4 years (8.2-8.5). The 5-year survival (5yOS) for overall, 40-49, 50-59, 60-69, 70-79 years was respectively 80.5%, 87.7%, 83.7%, 83.8% and 75.5%. The 5yOS for stages 0, I, II, III and IV was 95.2%, 92.6%, 89.4%, 71.1% and 47.1%. There was no significant difference in survival in stage I or II (p=0.058). Compared to women 50-59 years, death's risk was 2.3 times higher for women 70-79 years and 26% lower for women 40-49 years. Concerning stage I, the risk of death was 1.5, 4.1 and 8.6 times higher, and 34% lower, respectively, for stage II, III, IV and 0. Conclusions In Brazil, breast cancers are currently diagnosed in the early stages, although advanced cases persist. Survival rates may reflect improvements in screening, early detection and treatment. The results can reflect the current status of other regions or countries with similar health care conditions.

Download Full-text

Microvessel Density and Mammaglobin A Expression as Prognostic Markers in Molecular Types of Breast Cancer

Revista de Chimie ◽

10.37358/rc.19.7.7403 ◽

2019 ◽

Vol 70 (7) ◽

pp. 2671-2676

Author(s):

Adriana Andreea Jitariu ◽

Amalia Raluca Ceausu ◽

Adriana Meche ◽

Cristian Nica ◽

Amelia Burlea ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Microvessel Density ◽

Ductal Carcinoma ◽

Hot Spot ◽

Histopathological Diagnosis ◽

Breast Cancers ◽

Breast Cancer Patients ◽

Luminal A ◽

Mean Values

Increased microvessel density (MVD) values in breast cancer correlate with tumor growth and progression while mammaglobin (MGB) expression in tumor cells is associated with a favorable prognosis. We aim to evaluate and correlate MVD values with MGB expression in molecular types of breast cancer specimens and to determine their utility as prognostic biological markers. A number of 52 breast cancer specimens were included in the study. Specimens were processed for routine histopathological diagnosis followed by the molecular classification by means of estrogen (ER), progesterone (PR) and HER2 immunohistochemical reactions. After performing immunohistochemistry for CD34 and MGB, MVD evaluation was made using the �hot spot� method for each case and MGB was scored between 0 (negative) and +3 (strong positive) depending on the intensity and distribution of the staining. MGB expression in tumor cells and MVD mean values were extremely variable. The greatest MVD mean values were obtained in luminal B followed by HER2, luminal A and triple negative breast cancer (TNBC) (95.33, 69, 62, and 40, respectively). MGB expression in the tumor cells generally ranged from mild to weak and was strong only in a few invasive ductal carcinoma cases. In cases with TNBCs the expression of MGB in tumor cells was weak and focal or negative. This variability was noticed between the molecular types of breast cancers and even within the same molecular type. In a restricted number of cases, MGB positive tumors were associated with low MVD values while the negative cases were characterized by increased MVD mean values. The variable results we obtained regarding the correlation between MVD and MGB in breast cancer specimens may indicate a rather restricted use of MVD/MGB in estimating breast cancer patients� prognosis.

Download Full-text

Breast Cancer in Men: Clinical and Pathological Analysis of 817 Cases

American Journal of Men s Health ◽

10.1177/1557988320908109 ◽

2020 ◽

Vol 14 (4) ◽

pp. 155798832090810

Author(s):

Fernanda Servidoni Spreafico ◽

Cassio Cardoso-Filho ◽

Cesar Cabello ◽

Luis Otávio Sarian ◽

Luiz Carlos Zeferino ◽

...

Keyword(s):

Breast Cancer ◽

Ductal Carcinoma ◽

Prevalence Ratio ◽

Breast Cancer Diagnosis ◽

Cross Sectional Study ◽

Sectional Study ◽

Cross Sectional ◽

Histological Types ◽

The Mean ◽

Breast Cancer In Men

The objective of the current study was to describe breast cancer cases in men according to age, stage, and histology, calculating risks compared to women. It is a retrospective cross-sectional study of all breast cancer cases of the Hospital Cancer Registry of São Paulo state, Brazil, 2000–2015. Variables were age, sex, stage, and histology. Absolute numbers and proportions, Mann–Whitney test and prevalence ratio with 95% confidence interval were used. The study included 93,737 cases, of which 817 were males. The mean age at diagnosis was 60.3 years in men and 56.2 years in women ( p < .001). Stage II was the most common in both sexes (33.9% in men and 36.5% in women). Men had a higher frequency of stage III than women (PR 1.18, 95% CI 1.01–1.37). Stage 0 was significantly more common in women (PR 0.69, 95% CI 0.51–0.94). Ductal carcinoma and its variants were the most common histological types in both sexes (88.7% in men and 89.0% in women). Men had a higher frequency of rarer histological types such as papillary (PR 2.17, 95% CI 1.36–3.44) and sarcomas (PR 4.10, 95% CI 1.86–9.01). In conclusion, in men, breast cancer diagnosis occurred in more advanced ages and stages. Invasive ductal carcinoma was the primary histological type observed, although rarer types were more frequent.

Download Full-text

Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters

BMC Research Notes ◽

10.1186/s13104-019-4653-x ◽

2019 ◽

Vol 12 (1) ◽

Cited By ~ 5

Author(s):

Atif Ali Hashmi ◽

Kashif Ali Hashmi ◽

Muhammad Irfan ◽

Saadia Mehmood Khan ◽

Muhammad Muzzammil Edhi ◽

...

Keyword(s):

Breast Cancer ◽

Ductal Carcinoma ◽

Prognostic Significance ◽

Breast Cancer Subtypes ◽

Prognostic Parameters ◽

Ki67 Index ◽

Breast Cancers ◽

Cancer Subtypes ◽

Luminal B ◽

Cancer Management

Abstract Objectives Ki67 is the most commonly used marker to evaluate proliferative index in breast cancer, however no cutoff values have been clearly defined for high ki67 index. Cancer management should be according to loco-regional profile; therefore, we aimed to determine ki67 index in 1951 cases of intrinsic breast cancer subtypes and its association with other prognostic parameters in our set up. Results Triple negative breast cancers showed highest ki67 index (mean 50.9 ± 23.7%) followed by Her2neu (mean 42.6 ± 21.6%) and luminal B cancers (mean 34.9 ± 20.05%). Metaplastic and medullary breast cancers significantly showed higher ki67 index as compared to ductal carcinoma, NOS. No significant association of ki67 index was noted with any of the histologic parameters in different subtypes of breast cancer expect for tumor grade. Although, ki67 index is a valuable biomarker in breast cancer, however no independent prognostic significance of ki67 could be established in our study.

Download Full-text